C4 Therapeutics Doses First Patient in Key Phase 1b Multiple Myeloma Trial
summarizeSummary
C4 Therapeutics announced the dosing of the first patient in its Phase 1b trial evaluating cemsidomide in combination with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma. This trial is a significant step in the company's pipeline, leveraging a clinical collaboration supply agreement with Pfizer from October 2025, where Pfizer provides the FDA-approved elranatamab. For a clinical-stage biopharmaceutical company, initiating a new phase of a clinical trial, especially with a major pharma partner and an FDA-approved combination, is a material de-risking event and a positive advancement for its lead candidate. The company's strong cash position, extended through 2028 by a recent $116.9 million offering, supports this development. Investors will be watching for Phase 1b data, anticipated in mid-2027, and further updates on cemsidomide's broader development strategy, including plans for other combination agents in mid-2026.
At the time of this announcement, CCCC was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.9M. The 52-week trading range was $1.09 to $3.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.